Results 231 to 240 of about 45,189 (317)

Long-Standing Untreated or Inadequately Treated Seropositive Rheumatoid Arthritis in the Golden Age of Disease-Modifying Antirheumatic Drugs. [PDF]

Cureus
Arcilla CK, Kaeley GS, Thway M.
europepmc   +1 more source

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial. [PDF]

RMD Open
Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Konishi Y, Chonan S, Ikeda K, Camp HS, Tanaka Y.   +9 more
europepmc   +1 more source

Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis. [PDF]

Immun Ageing
Schwarz T, Almanzar G, Völkl S, Feuchtenberger M, Leierer J, Schmidt C, Deininger F, Tony HP, Schmalzing M, Prelog M.   +9 more
europepmc   +1 more source

Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. [PDF]

Arthritis Care Res (Hoboken)
Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA.   +7 more
europepmc   +1 more source

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. [PDF]

Arthritis Rheumatol
Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K.   +28 more
europepmc   +1 more source

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network. [PDF]

Front Pharmacol
Vitale A, Leone F, Caggiano V, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Ayumi Kawakami-Campos P, Hissaria P, Callisto A, Beecher M, Dagna L, Tomelleri A, Campochiaro C, Frassi M, Crisafulli F, Franceschini F, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Sfriso P, Bindoli S, Baggio C, Sbalchiero J, Sota J, Tufan A, Vasi I, Piga M, Cauli A, D'Agostino MA, De Paulis A, Mormile I, Mayrink Giardini HA, Cordeiro RA, Gavioli F, Lopalco G, Iannone F, Montecucco C, Monti S, Ruiz-Irastorza G, Soto-Peleteiro A, Triggianese P, Gurnari C, Viapiana O, Bixio R, Vitetta R, Conticini E, La Torre F, Ragab G, Batu ED, González-García A, Peña-Rodríguez M, Bocchia M, Wiesik-Szewczyk E, Jahnz-Rózyk K, de-la-Torre A, Balistreri A, Frediani B, Fabiani C, Cantarini L.   +59 more
europepmc   +1 more source

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database. [PDF]

Front Pharmacol
Xiong W, Li Y, Hu L, He G, Huang J.
europepmc   +1 more source

Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source

Trends in New Use of Disease-Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022. [PDF]

Arthritis Rheumatol
Yalamanchili P, Lee LY, Bushnell G, Mannion ML, Dave CV, Horton DB.   +5 more
europepmc   +1 more source